Boston Scientific: Lotus Edge Payout, Mesh Cases, ACURATE Charges

The Boston Scientific settlement currently paying out money is the $38.5 million Lotus Edge securities class action, which received final court approval in April 2024 and began distributing funds to eligible shareholders in April 2025. A second round of payments went out in February 2026, and additional distributions continue on a rolling basis. The claim filing deadline has passed. Separately, a new securities lawsuit was filed in March 2026 over the company’s electrophysiology business, transvaginal mesh litigation continues in state courts, and a federal Foreign Corrupt Practices Act investigation remains open.

The Lotus Edge Securities Settlement Now Paying Out

The case is In re Boston Scientific Corporation Securities Litigation, Case No. 1:20-cv-12225-ADB, in the U.S. District Court for the District of Massachusetts. It covers investors who purchased Boston Scientific common stock between September 16 and November 16, 2020, and were damaged by allegedly misleading statements about the Lotus Edge transcatheter aortic valve.1Bernstein Litowitz Berger & Grossmann LLP. Boston Scientific Corporation Securities Litigation

Investors alleged the company told the market the U.S. launch was “on track” to reach 150 hospital accounts in year one and described the device as “safe” and “simple,” while internal data showed manufacturing yield rates as low as 5 to 10 percent, delivery system malfunctions, and overstated account numbers. On November 17, 2020, Boston Scientific issued a global voluntary recall of all unused Lotus Edge inventory and shut down the entire Lotus valve platform, projecting $225 million to $300 million in pre-tax charges. The stock fell roughly 8 percent.2FindLaw. In Re Boston Scientific Corporation Securities Litigation

Excluded from the class are the defendants, their immediate families, company officers and directors during the class period, and affiliated entities.3Boston Scientific Securities Litigation. In Re Boston Scientific Corporation Securities Litigation – FAQ

Payment Status and Amounts

Claims administration closed on February 7, 2025, and the court approved the distribution plan on February 26, 2025. The first payment round went out on April 10, 2025, and a second distribution followed on February 10, 2026. More distributions will continue as long as funds remain.4Boston Scientific Securities Litigation. In Re Boston Scientific Corporation Securities Litigation Individual payout amounts are set by a court-approved allocation formula and are not publicly disclosed.

The Claim Deadline Has Passed

The filing deadline was May 28, 2024. No new claims are being accepted.1Bernstein Litowitz Berger & Grossmann LLP. Boston Scientific Corporation Securities Litigation If you filed a claim and have questions about your status, the claims administrator is JND Legal Administration, reachable at 877-595-0084 or info@BostonScientificSecuritiesLitigation.com.4Boston Scientific Securities Litigation. In Re Boston Scientific Corporation Securities Litigation

The New 2026 Electrophysiology Lawsuit

A separate securities class action was filed on March 5, 2026, in the same Massachusetts federal court. Troike v. Boston Scientific Corporation et al., Case No. 4:26-cv-40075, was assigned to Judge Julia E. Kobick.5Docket Alarm. Troike v. Boston Scientific Corporation Et Al

The complaint covers a proposed class period of July 23, 2025 through February 3, 2026, and alleges that executives described the U.S. electrophysiology segment, and the Farapulse pulsed field ablation platform in particular, as having “high single-digit growth” and “durable” competitive strength while knowing the growth was unsustainable, competitors were taking share, and reimbursement pressures were mounting.6ZLK. Troike v. Boston Scientific Corporation Complaint

On February 4, 2026, Boston Scientific reported fourth-quarter electrophysiology sales of $890 million, missed analyst estimates, and issued cautious 2026 guidance. The stock dropped more than 17 percent that day, the company’s worst single-session decline in over 25 years.7Reuters. Boston Scientific Shares Slide on Cautious 2026 Revenue Forecast CEO Mike Mahoney told analysts, “When you’re the highest market share leader in PFA, and competitors are coming out, we planned, and we do expect to lose some share.”8Star Tribune. Boston Scientific Stock

Named defendants alongside Mahoney are CFO Jonathan R. Monson, Chief Medical Officer Kenneth M. Stein, cardiology executive Joseph M. Fitzgerald, and electrophysiology president Nicholas Spadea-Anello.9ZLK. Boston Scientific Corporation Class Action Lawsuit The lead plaintiff deadline was May 4, 2026. No class has been certified and no substantive rulings have been issued.5Docket Alarm. Troike v. Boston Scientific Corporation Et Al There is no settlement fund and no payment process at this stage.

Transvaginal Mesh Cases and Verdicts

Women implanted with Boston Scientific transvaginal surgical mesh for pelvic organ prolapse or stress urinary incontinence have pursued injury claims for more than a decade, alleging complications including chronic pain, mesh erosion, infection, and irreversible incontinence.

Roughly 26,458 cases were consolidated in Multidistrict Litigation No. 2326 in the Southern District of West Virginia. The MDL was closed in 2021, but individual state-court cases continue to be filed. Boston Scientific has paid more than $400 million overall to resolve mesh claims, according to Drugwatch.10Drugwatch. Transvaginal Mesh Verdict and Settlement Milestones include a 2015 settlement of roughly 3,000 cases for $119 million, a Delaware verdict of $100 million later reduced to $10 million, and a Texas verdict of $73.4 million cut to $34 million.11TruLaw. Boston Scientific Vaginal Mesh Lawsuit In 2025, the Eleventh Circuit upheld a $26.7 million verdict for four plaintiffs. Women who believe they may have a claim need to consult a plaintiff’s attorney; there is no central federal MDL open to new filings.

Multistate Attorney General Settlement

In March 2021, Boston Scientific agreed to pay $188.6 million to 47 states and the District of Columbia to resolve allegations that it had deceptively marketed its mesh products by failing to disclose the full range of serious complications.12California Office of the Attorney General. California Department of Justice Announces $188.6 Million Multistate Settlement California and Washington led the investigation, joined as lead states by Florida, Indiana, Maryland, Ohio, South Carolina, and Texas.13Texas Attorney General. AG Paxton Announces $188.6 Million Multistate Settlement

The company also agreed to describe potential complications in plain language, disclose significant risks in provider training, register company-sponsored clinical studies on ClinicalTrials.gov, and disclose sponsorship roles when publishing clinical data. In Washington, funds went into a restitution fund for affected women, administered separately from private lawsuits. If you were implanted with Boston Scientific mesh, check with your state attorney general’s office to see whether your state runs a similar restitution process.14Washington Attorney General. AG Ferguson: Mesh Manufacturer Boston Scientific Will Pay More Than $88 Million

Open FCPA Investigation

Boston Scientific is under federal investigation for potential Foreign Corrupt Practices Act violations. It began after a whistleblower letter in March 2022 alleged improper payments in the company’s Vietnam operations. The SEC and the U.S. Attorney’s Office for the District of Massachusetts issued document subpoenas in late 2022 and early 2023. In its annual report filed March 19, 2025, the company said the inquiry had expanded beyond Vietnam to additional unnamed countries and that it was continuing to cooperate.15FCPA Professor. Scrutiny Updates No charges or settlement have been announced, so there is nothing here for a consumer or investor to claim.

ACURATE Valve Discontinuation and 2025 Litigation Charges

On May 28, 2025, Boston Scientific announced it was discontinuing worldwide sales of its ACURATE neo2 and ACURATE Prime transcatheter aortic valve systems and ending all related commercial, clinical, research, and manufacturing activity. The announcement followed a Lancet study finding that patients who received the ACURATE neo2 had a 6.6 percentage point higher rate of death, stroke, and rehospitalization at one year compared to competing valves.16Medscape. Acurate Heart Valves Halted After Consequential Study The company also cited regulator discussions that had raised the clinical and regulatory bar for keeping existing approvals in place.17Cardiovascular Business. Boston Scientific Pulls Plug on TAVR Devices After Failing to Gain FDA Approval The ACURATE neo2 had been used in 50 countries but never received FDA approval in the United States. Boston Scientific reported $194 million in litigation-related charges for 2025 in its year-end results.18Boston Scientific. Boston Scientific Announces Results for Fourth Quarter and Full Year 2025 No consumer settlement fund has been announced tied to this product.